Skip to main content
Premium Trial:

Request an Annual Quote

$10M Genome X Prize Will Go to First Team to Map 100 Human Genomes in 10 Days

NEW YORK (GenomeWeb News) — The X Prize Foundation today announced its $10 million Archon X Prize for Genomics, which will go to the first team to create a technology that can map 100 human genomes in 10 days.

According to the Foundation, the prize “is designed to usher in a new era of personalized preventative medicine.”

Three teams are currently enrolled in the competition: VisiGen Biotechnologies, led by Susan Hardin; 454 Life Sciences, led by CEO Christopher McLeod; and a group comprising the Westheimer Institute for Science and Technology, the Foundation for Applied Molecular Evolution, and Firebird Biomolecular Sciences. This group will be led by Steve Benner.
“Many other companies have inquired and more teams are expected to register soon,” the X Prize Fundation said.
The prize was announced at a press conference today at the National Press Club in Washington, DC. On hand were Craig Venter; Francis Collins; Anousheh Ansari, the first female private space explorer and co-founder and chairman of Prodea Systems; Sharon Terry, president and CEO of the Genetic Alliance; Billy Tauzin, president and CEO of the Pharmaceutical Research and Manufacturing Association; and Stewart Blusson, president of Archon Minerals, which became the title sponsor of the prize after a “generous multi-million dollar” donation by Blusson.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.